TRPC6 recombinant proteins and antibodies

Transient Receptor Potential Canonical 6, also known as TRPC6, is a member of the canonical subfamily of transient receptor potential (TRP) channels. It functions as a non-selective cation channel that mediates calcium (Ca²⁺) and sodium (Na⁺) influx into cells. TRPC6 is widely expressed in the heart, kidney, lung, and nervous system, playing vital roles in cell proliferation, migration, apoptosis, and vascular smooth muscle contraction. Dysregulation or overactivation of TRPC6 has been implicated in multiple pathological conditions, including glomerulosclerosis, pulmonary hypertension, cardiac hypertrophy, epilepsy, and neurodegenerative diseases.

In drug discovery, TRPC6 is primarily targeted for antagonist development, though agonists are also being explored for neurological indications. TRPC6 inhibition can ameliorate renal diseases such as focal segmental glomerulosclerosis (FSGS) and diabetic nephropathy, while TRPC6 activation may offer neuroprotective effects. Notably, Goldfinch Bio developed GFB-887 (GB-002), a small-molecule TRPC6 inhibitor that entered clinical trials for kidney diseases including FSGS. Global pharmaceutical leaders such as Bayer, Boehringer Ingelheim, and GlaxoSmithKline are also advancing programs targeting TRPC6 modulators. In China, companies like Shenzhen Salubris Pharmaceuticals, WuXi AppTec, and Junshi Biosciences are investing in TRP channel-related innovation for cardiovascular and renal disorders.

Overall, TRPC6 represents a promising therapeutic target that bridges calcium signaling, cellular stress responses, and metabolic regulation. With growing mechanistic insights and ion channel–focused drug discovery platforms, TRPC6 is poised to become an emerging target in precision medicine for cardiovascular, renal, and neurological diseases.

To assist in the development of TRPC6-targeted small molecule drugs, DIMA BIOTECH can now provide full-length TRPC6 recombinant membrane protein developed by its nanodisc membrane protein platform. TRPC6 nanodisc is an optimal solution for screening small molecules targeting TRPC6 with its natural structure. Furthermore, DIMA BIOTECH has also prepared a TRPC6 single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days.